Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

达拉图穆马 医学 内科学 肿瘤科 临床试验 多发性骨髓瘤 来那度胺
作者
Melody Becnel,Michael Rubin,Ranjit Nair,Elisabet E. Manasanch,Hans C. Lee,Krina K. Patel,Swaminathan P. Iyer,Sheeba K. Thomas,Donna M. Weber,Robert Z. Orlowski
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 3258-3258 被引量:6
标识
DOI:10.1182/blood-2018-99-115663
摘要

Abstract Introduction Notable advances have been made in multiple myeloma management (MM) in recent years. The monoclonal antibodies daratumumab (dara) and elotuzumab (elo) are integral in the management of relapsed/refractory MM and are moving into the frontline setting for transplant ineligible patients. Despite many trials evaluating the efficacy of these agents, there is no consensus on the optimal integration of these agents into the current paradigm of MM management. There is a paucity of data to guide the selection of one antibody over the other, and little is known about whether the use of one prior antibody alters the efficacy of other agents in subsequent lines of therapy. We retrospectively analyzed MM patients treated with both elo and dara during the course of their disease to assess whether the sequence of elo followed by dara or dara followed by elo led to better outcomes. Methods We reviewed the records of MM patients ≥ 18 years old who received both dara and elo at any time during treatment at MD Anderson Cancer Center. We evaluated the time to next treatment (TTNT), defined as the start date of one treatment to the start of the next treatment, and the overall response rate (ORR) (partial response or greater) to dara and elo. TTNT and ORR were calculated for dara when administered as the first antibody during treatment and to dara when administered as the second antibody (elo given during prior lines of treatment). We evaluated TTNT and ORR when elo was administered as the first antibody during treatment and to elo when administered as the second antibody (dara given during prior lines of treatment). The association with categorical patient variables (age, race, immunoglobulin class, number of prior lines of therapy, agent co-administered with the second monoclonal antibody given) was analyzed using Fisher exact tests. Outcomes were estimated using the Kaplan-Meier method and differences in survival among groups were assessed using two-sided log-rank tests. Results We identified 56 patients treated with both dara and elo. We excluded 6 for missing data; 56% of the 50 patients were male; 70% were Caucasian; 56% with IgG subclass paraprotein; 66% kappa light chain restricted. Patients were heavily pre-treated; most with >5 lines of therapy prior to initiation of dara or elo. Elo was the first agent received in 64% of patients. Independent of treatment order, the ORR to elo and dara were 72% and 88% respectively. When elo was administered prior to dara (elo first), the ORR was 78%, and 61% when administered after dara (elo second). When dara was administered prior to elo (dara first), the ORR was 89%, and 88% when administered after elo (dara second). There was no statistical difference in ORR (78% vs 89%) for the initial antibody given, but there was a significant difference in ORR (61% vs. 88%) to the agent given second (p=0.04). Of the variables assessed, only the antibody class had a statistically significant association with outcomes; IgG was associated with better responses when elo was administered as the second agent. TTNT analysis included 47 (of 50) evaluable patients. With elo given first, median TTNT was 6.28 months, and 2.23 months when given second. With dara given first, median TTNT was 8.97 months and 4.60 months when given second. There was no statistically significant difference in TTNT for either the first or second agent administered. There was a statistically significant improvement in TTNT in Caucasian patients compared to other races when elo was given first, but no other clinical factor association was statistically significant. Conclusions Our data, though retrospective and single-center, demonstrate that responses to dara are similar whether administered as the first or second monoclonal antibody used in the treatment of MM. However, prior treatment with dara negatively impacts responses to elo in subsequent lines of therapy. Similarly, independent of the sequence of administration, TTNT was prolonged with dara compared to elo. Our findings suggest that elo followed by dara may be the preferred sequence of monoclonal antibody therapy as responses to elo decreased when administered after dara, but responses to dara were stable irrespective of elo administration. These findings warrant further investigation particularly as dara is now being used more often in the frontline setting. Further evaluation is also needed to determine any association with additional patient factors such as cytogenetics. Disclosures Lee: Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies Corporation: Consultancy; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Chugai Biopharmaceuticals: Consultancy; Takeda Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees. Patel:Poseida Therapeutics, Inc.: Research Funding; Takeda: Research Funding; Abbvie: Research Funding; Celgene: Research Funding. Thomas:Amgen Inc: Research Funding; Celgene: Research Funding; Bristol Myers Squibb Inc.: Research Funding; Array Pharma: Research Funding; Acerta Pharma: Research Funding. Orlowski:Janssen Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; BioTheryX, Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Millenium Pharmaceuticals: Consultancy, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Consultancy; Poseida: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
coff完成签到,获得积分10
1秒前
2秒前
研友_ZG4ml8发布了新的文献求助10
2秒前
学术的刘完成签到,获得积分10
2秒前
Allen完成签到,获得积分10
3秒前
牧芷珊完成签到,获得积分10
3秒前
阿柠完成签到,获得积分10
3秒前
研友_Zbb4mZ完成签到,获得积分10
3秒前
三七二一完成签到,获得积分10
3秒前
4秒前
JamesPei的应助被爱在西元前采纳,获得10
4秒前
奋斗蝴蝶发布了新的文献求助10
5秒前
陈zw完成签到,获得积分10
5秒前
5秒前
zzzzlllll完成签到,获得积分10
5秒前
Sue完成签到,获得积分10
6秒前
rrr完成签到,获得积分10
6秒前
ZYX完成签到,获得积分10
6秒前
喜悦白玉发布了新的文献求助10
7秒前
ZJ完成签到,获得积分10
7秒前
7秒前
wanci的应助被瘦瘦滢采纳,获得10
7秒前
拉普拉斯开始变换完成签到,获得积分10
7秒前
molihuakai的应助被方苠采纳,获得10
7秒前
feiyue126发布了新的文献求助10
7秒前
8秒前
skmksd发布了新的文献求助10
8秒前
登山者完成签到,获得积分10
8秒前
幸运鱼完成签到,获得积分10
8秒前
小明同学呀完成签到,获得积分10
9秒前
yi完成签到,获得积分10
9秒前
9秒前
joyli完成签到,获得积分10
9秒前
阿白完成签到,获得积分10
10秒前
10秒前
李健的小迷弟的应助被Lily采纳,获得10
10秒前
嘻嘻哈公主完成签到 ,获得积分20
10秒前
哈尼完成签到,获得积分10
10秒前
酷酷冷亦完成签到,获得积分10
10秒前
苹果骑士完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039